|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP10D |
Gene summary for ATP10D |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP10D | Gene ID | 57205 |
| Gene name | ATPase phospholipid transporting 10D (putative) | |
| Gene Alias | ATPVD | |
| Cytomap | 4p12 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9P241 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57205 | ATP10D | P75T-E | Human | Esophagus | ESCC | 7.99e-20 | 3.73e-01 | 0.1125 |
| 57205 | ATP10D | P76T-E | Human | Esophagus | ESCC | 2.25e-03 | 9.58e-02 | 0.1207 |
| 57205 | ATP10D | P79T-E | Human | Esophagus | ESCC | 2.77e-03 | 4.09e-02 | 0.1154 |
| 57205 | ATP10D | P80T-E | Human | Esophagus | ESCC | 2.13e-21 | 5.91e-01 | 0.155 |
| 57205 | ATP10D | P83T-E | Human | Esophagus | ESCC | 6.19e-21 | 4.39e-01 | 0.1738 |
| 57205 | ATP10D | P89T-E | Human | Esophagus | ESCC | 4.73e-02 | 3.77e-01 | 0.1752 |
| 57205 | ATP10D | P91T-E | Human | Esophagus | ESCC | 4.47e-07 | 4.68e-01 | 0.1828 |
| 57205 | ATP10D | P107T-E | Human | Esophagus | ESCC | 1.17e-21 | 5.77e-01 | 0.171 |
| 57205 | ATP10D | P127T-E | Human | Esophagus | ESCC | 4.92e-05 | 8.68e-02 | 0.0826 |
| 57205 | ATP10D | P128T-E | Human | Esophagus | ESCC | 2.72e-05 | 1.33e-01 | 0.1241 |
| 57205 | ATP10D | P130T-E | Human | Esophagus | ESCC | 2.30e-10 | 1.41e-01 | 0.1676 |
| 57205 | ATP10D | C04 | Human | Oral cavity | OSCC | 6.20e-16 | 9.64e-01 | 0.2633 |
| 57205 | ATP10D | C21 | Human | Oral cavity | OSCC | 3.21e-20 | 7.86e-01 | 0.2678 |
| 57205 | ATP10D | C30 | Human | Oral cavity | OSCC | 2.20e-21 | 1.02e+00 | 0.3055 |
| 57205 | ATP10D | C43 | Human | Oral cavity | OSCC | 3.24e-04 | 1.20e-01 | 0.1704 |
| 57205 | ATP10D | C51 | Human | Oral cavity | OSCC | 1.61e-13 | 8.60e-01 | 0.2674 |
| 57205 | ATP10D | C06 | Human | Oral cavity | OSCC | 2.64e-03 | 1.01e+00 | 0.2699 |
| 57205 | ATP10D | EOLP-1 | Human | Oral cavity | EOLP | 1.43e-02 | 2.55e-01 | -0.0202 |
| 57205 | ATP10D | SYSMH1 | Human | Oral cavity | OSCC | 1.77e-04 | 1.51e-01 | 0.1127 |
| 57205 | ATP10D | SYSMH2 | Human | Oral cavity | OSCC | 1.09e-09 | 2.43e-01 | 0.2326 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00157483 | Oral cavity | EOLP | organophosphate ester transport | 28/2218 | 140/18723 | 3.66e-03 | 2.05e-02 | 28 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATP10D | SNV | Missense_Mutation | rs149296162 | c.2045N>A | p.Ser682Asn | p.S682N | Q9P241 | protein_coding | tolerated(0.27) | benign(0.014) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
| ATP10D | SNV | Missense_Mutation | c.2279G>C | p.Gly760Ala | p.G760A | Q9P241 | protein_coding | deleterious(0.04) | possibly_damaging(0.899) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD | |
| ATP10D | SNV | Missense_Mutation | c.3184A>G | p.Ser1062Gly | p.S1062G | Q9P241 | protein_coding | deleterious(0.01) | probably_damaging(0.966) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ATP10D | SNV | Missense_Mutation | novel | c.521N>T | p.Asp174Val | p.D174V | Q9P241 | protein_coding | deleterious(0) | possibly_damaging(0.824) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ATP10D | SNV | Missense_Mutation | c.830N>C | p.Arg277Thr | p.R277T | Q9P241 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ATP10D | SNV | Missense_Mutation | c.736N>A | p.Glu246Lys | p.E246K | Q9P241 | protein_coding | deleterious(0.01) | probably_damaging(0.967) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ATP10D | SNV | Missense_Mutation | novel | c.544C>A | p.Arg182Ser | p.R182S | Q9P241 | protein_coding | deleterious(0) | possibly_damaging(0.527) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP10D | SNV | Missense_Mutation | novel | c.3178G>T | p.Asp1060Tyr | p.D1060Y | Q9P241 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP10D | SNV | Missense_Mutation | c.1234G>A | p.Glu412Lys | p.E412K | Q9P241 | protein_coding | tolerated(0.07) | benign(0.41) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| ATP10D | SNV | Missense_Mutation | rs763021315 | c.4115N>A | p.Gly1372Glu | p.G1372E | Q9P241 | protein_coding | tolerated(1) | benign(0) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |